Abstract
The skeleton is constantly being remodelled through the simultaneous resorption of bone and formation of new bone. Significant effects on bone metabolism are produced due to cancer treatment especially of breast and prostate origin, even in the absence of bone metastases. These pathological changes are known as cancer treatment-induced bone loss. Bone mass loss and osteoporosis may cause an increased risk of fractures due to a reduction in bone volume and microarchitectural deterioration. On the other hand, the skeleton is both the most common organ affected by metastatic cancer and the site that produces the greatest morbidity for patients.
Recent advances in our understanding of bone biology and the pathways by which cancer metastasizes and spreads to bone have contributed to the development of several important new drugs targeting these processes. This article summarizes our current knowledge and recommendations to advanced biology of metastasis, focusing on breast and prostate cancer.
Keywords: Aromatase inhibitors, alendronate, bisphosphonate, breast cancer, denosumab, mevalonate pathway, osteoporosis, prostate cancer, RANK, zoledronic acid.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Osteoporosis in Patients with Breast and Prostate Cancer: Effect of Disease and Treatment Modalities
Volume: 13 Issue: 2
Author(s): Ioannis Legakis and Konstantinos Syrigos
Affiliation:
Keywords: Aromatase inhibitors, alendronate, bisphosphonate, breast cancer, denosumab, mevalonate pathway, osteoporosis, prostate cancer, RANK, zoledronic acid.
Abstract: The skeleton is constantly being remodelled through the simultaneous resorption of bone and formation of new bone. Significant effects on bone metabolism are produced due to cancer treatment especially of breast and prostate origin, even in the absence of bone metastases. These pathological changes are known as cancer treatment-induced bone loss. Bone mass loss and osteoporosis may cause an increased risk of fractures due to a reduction in bone volume and microarchitectural deterioration. On the other hand, the skeleton is both the most common organ affected by metastatic cancer and the site that produces the greatest morbidity for patients.
Recent advances in our understanding of bone biology and the pathways by which cancer metastasizes and spreads to bone have contributed to the development of several important new drugs targeting these processes. This article summarizes our current knowledge and recommendations to advanced biology of metastasis, focusing on breast and prostate cancer.
Export Options
About this article
Cite this article as:
Legakis Ioannis and Syrigos Konstantinos, Osteoporosis in Patients with Breast and Prostate Cancer: Effect of Disease and Treatment Modalities, Endocrine, Metabolic & Immune Disorders - Drug Targets 2013; 13 (2) . https://dx.doi.org/10.2174/18715303112129990027
DOI https://dx.doi.org/10.2174/18715303112129990027 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy
Current Drug Targets Overview of the Role of Macrophage Migration Inhibitory Factor (MIF) in Inflammatory Bowel Disease
Current Pharmaceutical Design HGF and RhoGTPases in Cancer Cell Motility
Current Signal Transduction Therapy microRNAs and Esophageal Cancer - Implications for Pathogenesis and Therapy
Current Pharmaceutical Design Prioritizing Disease Genes by Using Search Engine Algorithm
Current Bioinformatics RGD Peptide–mediated Molecular Imaging for Targeting Integrin Alpha(v) Beta(3) in Tumors: A Review
Current Medical Imaging Can Untargeted Metabolomics Be Utilized in Drug Discovery/Development?
Current Topics in Medicinal Chemistry Generating Recombinant Antibodies for Research, Diagnostics and Therapy Using Phage Display
Current Biotechnology Small Molecule Inhibitors of Stat3 Signaling Pathway
Current Cancer Drug Targets Photoacoustic Detection and Imaging of Cancer Using Nanoparticles as Optical Contrast Agents
Recent Patents on Nanomedicine PET Designated Flouride-18 Production and Chemistry
Current Topics in Medicinal Chemistry Statin Treatment and the Natural History of Atherosclerotic-Related Diseases: Pathogenic Mechanisms and the Risk-Benefit Profile
Current Pharmaceutical Design Oxidative Stress, Pro-Inflammatory Cytokines, and Antioxidants Regulate Expression Levels of MicroRNAs in Parkinson’s Disease
Current Aging Science Biological Role of Formaldehyde, and Cycles Related to Methylation, Demethylation, and Formaldehyde Production
Mini-Reviews in Medicinal Chemistry Natural Bioactive Compounds as Emerging Therapeutic Molecules Against Breast Cancer: Emphasis on the Role of Phytoestrogens
Current Drug Targets Biomedical Applications of Carbon Nanotubes: A Critical Review
Current Drug Delivery [6]-gingerol as a Cancer Chemopreventive Agent: A Review of Its Activity on Different Steps of the Metastatic Process
Mini-Reviews in Medicinal Chemistry Anti-Tumor Effects of Osthole on Different Malignant Tissues: A Review of Molecular Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Botulinum Toxin a in Prostate Disease: A Venom from Bench to Bed-Side
Current Drug Delivery miR-221/222 Confers Radioresistance in Glioblastoma Cells Through Activating Akt Independent of PTEN Status
Current Molecular Medicine